Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAC-253
- Development stage
- Preclinical
- Lead developer
- Saccharo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SAC-253 is a first-in-class antibody-drug conjugate (ADC) developed by Saccharo Inc. that targets de-N-acetyl-polysialic acid (dPSA). dPSA is a unique, highly conserved polysaccharide specifically expressed on the surface of various cancer cells, including pancreatic, lung, breast, and prostate cancers, but is absent in normal tissues. It is typically found linked to the nuclear protein nucleolin on the cell surface and is implicated in tumor immune evasion. SAC-253 is designed to selectively bind to dPSA-expressing tumor cells and deliver a cytotoxic payload, thereby inducing targeted cell death while minimizing off-target effects. The drug is currently in preclinical development.
- Other names
- SAC-253-Saccharo-dPSA (de-N-acetyl-polysialic acid)-ADC
02
Targets
dPSA (de-N-acetyl-polysialic acid)
Beyond the preview
Go deeper on SAC-253.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAC-253.